Evidence map›Paper›PMID 25599015›Full record

ArticlePhotonics & lasers in medicine2013

Techniques for fluorescence detection of protoporphyrin IX in skin cancers associated with photodynamic therapy.

Kishore R Rollakanti, Stephen C Kanick, Scott C Davis, Brian W Pogue, Edward V Maytin

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Photonics & lasers in medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04223570 (Portable Measurement of Protoporphyrin IX in the Skin), which is not on this map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04223570 completednot on this mapstarted 2022, after this paper: background citation

Portable Measurement of Protoporphyrin IX in the Skin

TypeobservationalSponsorDartmouth-Hitchcock Medical CenterRan2022 to 2025Enrolled219ConditionsPhotodynamic Therapy, Protoporphyrin IXArmsPortable Apple Smart Phone Protoporphyrin IX Spectrometer Camera
3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 63 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Effects of serum albumin on the photophysical characteristics of synthetic and endogenous protoporphyrin IX.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2022
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Protoporphyrin IX: the Good, the Bad, and the Ugly.The Journal of pharmacology and experimental therapeutics · 2016
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Kishore R RollakantiDepartment of Chemical and Biomedical Engineering, Cleveland State University, 2121 Euclid Avenue, Cleveland, OH 44115, USA; and Department of Biomedical Engineering, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Stephen C KanickThayer School of Engineering, Dartmouth College, 14 Engineering Drive, Hanover, NH 03755, USA.
Scott C DavisThayer School of Engineering, Dartmouth College, 14 Engineering Drive, Hanover, NH 03755, USA.
Brian W PogueThayer School of Engineering, Dartmouth College, 14 Engineering Drive, Hanover, NH 03755, USA.
Edward V MaytinDepartment of Chemical and Biomedical Engineering, Cleveland State University, 2121 Euclid Avenue, Cleveland, OH 44115, USA; Department of Biomedical Engineering, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA; and Department of Dermatology, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Dartmouth College · USCleveland State University · US

Funding

Small Molecule Enhancers of Photodynamic Therapy for Skin CancerP01CA084203 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Bryan Quilty Spring · 2001 to 2026
$27.9M
NCI NIH HHS P01 CA084203
6 · The paper itself

Abstract

Photodynamic therapy (PDT) is a treatment modality that uses a specific photosensitizing agent, molecular oxygen, and light of a particular wavelength to kill cells targeted by the therapy. Topically administered aminolevulinic acid (ALA) is widely used to effectively treat cancerous and precancerous skin lesions, resulting in targeted tissue damage and little to no scarring. The targeting aspect of the treatment arises from the fact that ALA is preferentially converted into protoporphyrin IX (PpIX) in neoplastic cells. To monitor the amount of PpIX in tissues, techniques have been developed to measure PpIX-specific fluorescence, which provides information useful for monitoring the abundance and location of the photosensitizer before and during the illumination phase of PDT. This review summarizes the current state of these fluorescence detection techniques. Non-invasive devices are available for point measurements, or for wide-field optical imaging, to enable monitoring of PpIX in superficial tissues. To gain access to information at greater tissue depths, multi-modal techniques are being developed which combine fluorescent measurements with ultrasound or optical coherence tomography, or with microscopic techniques such as confocal or multiphoton approaches. The tools available at present, and newer devices under development, offer the promise of better enabling clinicians to inform and guide PDT treatment planning, thereby optimizing therapeutic outcomes for patients.

Indexed as

fluorescencephotodynamic therapyprotoporphyrin IXtreatment planning

Identifiers

PMID25599015
PMCPMC4295789
OpenAlexW1971891579

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.